Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease | Zendy

C. Alex Wiles | Zendy; Nisha Shah | Zendy; Jake Bell | Zendy; Baldeep Pabla | Zendy; Elizabeth Scoville | Zendy; Robin Dalal | Zendy; Dawn B. Beaulieu | Zendy; David A. Schwartz | Zendy; Sara Horst | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease

Author(s) -

C. Alex Wiles,

Nisha Shah,

Jake Bell,

Baldeep Pabla,

Elizabeth Scoville,

Robin Dalal,

Dawn B. Beaulieu,

David A. Schwartz,

Sara Horst

Publication year - 2021

Publication title -

crohn s and colitis 360

Language(s) - English

Resource type - Journals

ISSN - 2631-827X

DOI - 10.1093/crocol/otab075

Subject(s) - tofacitinib , medicine , ulcerative colitis , inflammatory bowel disease , refractory (planetary science) , disease , cohort , gastroenterology , crohn's disease , rheumatoid arthritis , physics , astrobiology

Background Tofacitinib has been approved for moderate-to-severe ulcerative colitis and studied in Crohn’s disease. Understanding medication adherence to oral medications in severe disease is essential. Methods We retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Adherence was measured by proportion of days covered. Results Sixty-three patients were identified. All patients failed at least one prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn’s disease. Significant clinical and endoscopic response was seen. Conclusion Adherence was high in a cohort with highly refractory disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research